This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
by Zacks Equity Research
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
by Zacks Equity Research
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
by Zacks Equity Research
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
by Zacks Equity Research
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
by Zacks Equity Research
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 10.91% and 9.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Ionis Pharmaceuticals (IONS) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
by Zacks Equity Research
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
by Zacks Equity Research
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.
Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 92.31% and 77.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
by Zacks Equity Research
FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
by Zacks Equity Research
The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).